Alexion Up 2.5% on Mixed Results
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned $1.13 per share on sales of $753.12 million for its second quarter, missing the bottom-line consensus estimate by $0.04 but beating the top-line mark by $9.1 million. Revenue rose by 18.4% year-over-year as demand remained brisk for the company’s core Soliris product. Management anticipates non-GAAP EPS of $4.50-to-$4.65 on revenue of $3.05 billion-to-$3.10 billion for the full year. Within our database of 766 active funds, 37 hedge funds owned shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) at the end of the first quarter.
Ariad Spikes on Earnings Beat
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares are over 10% higher after the company reported second quarter GAAP EPS of $0.56 on sales of $68.13 million. The results were ahead of estimates by a whopping $0.67 per share and $7.49 million respectively. Although a big reason for the beat was a one-time revenue recognition measure of $25.5 million related to cumulative shipments of Iclusig in France, the company nevertheless achieved 50% year-over-year growth in U.S sales during the quarter. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is also making progress in terms of its pipeline, having initiated a rolling NDA submission for brigatinib during the quarter. 26 funds in our system owned $296.02 million worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares on March 31, which accounted for 24.40% of the float.
Goldcorp Off 5% on the Back of Lower Production Numbers
Goldcorp Inc. (USA) (NYSE:GG) reported a second quarter net loss of $0.09 per share, sharply lower than the net earnings of $0.47 per share that the company reported for the same quarter of last year. Like its revenue, which missed the consensus target by $152.66 million, the gold miner’s bottom-line results also missed analyst estimates, by $0.11 per share. Although production was slightly lower than expected for the quarter at 613,400 ounces of gold with all-in sustaining costs of $1,067 per ounce, the company reaffirmed its 2016 production guidance of 2.8 million-to-3.1 million ounces and an AISC of between $850 and $925 per ounce. Jim Simons‘ Renaissance Technologies was one of the top shareholders of Goldcorp Inc. (USA) (NYSE:GG) on March 31, owning 3.59 million shares.